Pancreatic Cancer Research

ResearcherCornell UniversityActive in the last 2 years

Fergus Keane

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6651-2090; OpenAlex author ID A5066922986. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
40
Papers, trials and grants by year

2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers · 2026: 2 papers

Papers 9

  1. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Co-author DOI 10.1038/s41591-026-04299-5↗
  2. POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer Co-author DOI 10.64898/2026.03.15.711961↗
  3. Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort. Co-author DOI 10.1093/jnci/djae269↗
  4. Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf139↗
  5. Morbidity and mortality in patients with stage IV pancreatic adenocarcinoma and acute cholangitis: Outcomes and risk prognostication. Co-author DOI 10.1016/j.pan.2024.05.515↗
  6. Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease. Co-author DOI 10.1093/jnci/djae095↗
  7. Pancreatic Cancer: BRCA Targeted Therapy and Beyond. Co-author DOI 10.3390/cancers15112955↗
  8. Incidence of Pancreatic Cancer by Age and Sex in the US From 2000 to 2018. Co-author DOI 10.1001/jama.2022.2309↗
  9. Homologous Recombination Deficiency in Pancreatic Cancer: Poly (ADP-ribose) Polymerase Inhibition, Checkpoint Inhibition, or a Combination of Both? Co-author DOI 10.1200/po.22.00141↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eileen Mary O'Reilly · 8 shared papers, 2022–2026 · strength 1.65
  2. Wungki Park · 7 shared papers, 2022–2026 · strength 1.39
  3. Marinela Capanu · 5 shared papers, 2024–2026 · strength 0.89
  4. Anna M. Varghese · 5 shared papers, 2024–2026 · strength 0.89
  5. Kenneth H. Yu · 5 shared papers, 2024–2026 · strength 0.89
  6. Fiyinfolu O. Balogun · 4 shared papers, 2024–2026 · strength 0.72
  7. Alice Chia-Chi Wei · 3 shared papers, 2024–2025 · strength 0.53
  8. Darren Cowzer · 3 shared papers, 2024–2025 · strength 0.53
  9. Anupriya Singhal · 3 shared papers, 2024–2025 · strength 0.53
  10. Vinod P. Balachandran · 2 shared papers, 2025–2026 · strength 0.36
  11. Kevin C. Soares · 2 shared papers, 2025–2026 · strength 0.36
  12. Fionnuala Crowley · 2 shared papers, 2025 · strength 0.36
  13. Mengmeng Du · 1 shared paper, 2022 · strength 0.26
  14. Thomas Theodor Werner Seufferlein · 1 shared paper, 2023 · strength 0.24
  15. Benjamin D. Greenbaum · 1 shared paper, 2026 · strength 0.19
  16. Olca Baştürk · 1 shared paper, 2026 · strength 0.19
  17. Dana Pe'er · 1 shared paper, 2026 · strength 0.19
  18. Benoı̂t Rousseau · 1 shared paper, 2026 · strength 0.19
  19. Caitlin A. McIntyre · 1 shared paper, 2026 · strength 0.19
  20. Akimasa Hayashi · 1 shared paper, 2026 · strength 0.19
  21. Haochen Zhang · 1 shared paper, 2026 · strength 0.19
  22. Agnel Sfeir · 1 shared paper, 2026 · strength 0.19
  23. Danny N. Khalil · 1 shared paper, 2026 · strength 0.19
  24. Marc Hilmi · 1 shared paper, 2026 · strength 0.19
  25. Nuray Tezcan · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.